Amgen stock falls as analysts mull over weight loss drug’s bone density data

Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.

Nov 13, 2024 - 10:00
 0  3
Amgen stock falls as analysts mull over weight loss drug’s bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.